TP53 and cancer: Pathogenic variants (PVs) in TP53 are found in nearly 50% of all human cancers, with most PVs occurring within the DNA-binding domain of p53 [1, 2] and resulting in highly stabilized mutant p53 (mutp53) proteins that not only lose their tumor suppressor activity but often even acquire oncogenic gain-of-function.